Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction PR...
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance PR Newswire LAVAL, Quebec, Feb. 24, 2021 LAVAL, Quebec, Feb. 24, 2021 /PRNewswire/...
Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium PR...
Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses PR Newswire LAVAL, QC, Oct. 27, 2020 First Preloaded Toric Available in the...
Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting PR Newswire LAVAL, QC, Oct. 22, 2020 Eleven Scientific Posters to...
Bausch Health Releases Annual Corporate Social Responsibility Report PR Newswire LAVAL, QC, Sept. 23, 2020 Includes Special Report on Global COVID-19 Response and Commitment to Diversity &...
Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare Conference PR Newswire LAVAL, QC, Sept. 9, 2020 LAVAL, QC, Sept. 9, 2020 /PRNewswire/ -- Bausch Health Companies...
Bausch Health Resolves Legacy SEC Investigation PR Newswire LAVAL, QC, July 31, 2020 LAVAL, QC, July 31, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the...
Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference PR Newswire LAVAL, Quebec, May 21, 2020 LAVAL, Quebec, May 21, 2020 /PRNewswire/ -- Bausch Health Companies Inc...
Bausch Health Announces 2020 Annual Meeting Of Shareholder Results PR Newswire LAVAL, Quebec, April 29, 2020 LAVAL, Quebec, April 29, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX:...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約